Top-News
Dienstleistung USA

Omeros News

Aktie
WKN:  A0NBFF ISIN:  US6821431029 US-Symbol:  OMER
3,398 €
+0,022 €
+0,65%
06.05.24 19:02:35
Handeln Depot/Watchlist
Aktienanzahl *
62,74 Mio.
Marktkapitalisierung *
217,44 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 20.04.2023

Omeros News

15.10.15 - PR Newswire
Omeros Announces OMIDRIAssure™ to Expand Patient Access to Omidria®
Omeros Announces OMIDRIAssure™ to Expand Patient Access to Omidria® -- Ensures Access to Benefits of Omidria for Cataract Patients, Surgeons and Facilities -- PR Newswire
19.08.15 - PR Newswire
Critical Alerts For Chesapeake Energy, Omeros, Second Sight Medical Products Inc., Denbury Resources and Whiting Petroleum Released By InvestorsObserver
Critical Alerts For Chesapeake Energy, Omeros, Second Sight Medical Products Inc., Denbury Resources and Whiting Petroleum Released By InvestorsObserver PR Newswire
19.08.15 - Der Aktionär TV
Omeros-Aktie: Wahnsinn! 95 Prozent in 1 Tag
Die Omeros-​Aktie hat gestern ein wahres Feuerwerk am Markt gezündet. Sagenhafte 95 Prozent Kursgewinn standen am Dienstag unterm Strich. Sie fragen sich jetzt was genau ...
18.08.15 - PR Newswire
Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial
Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial -- Company Plans for Phase 3 Program Based on Consistent Response in TMA Patients -- PR Newswire
17.08.15 - PR Newswire
Omeros Announces Plan to File Infringement Suit Against ANDA Filer
Omeros Announces Plan to File Infringement Suit Against ANDA Filer PR Newswire
10.08.15 - PR Newswire
Omeros Corporation Reports Second Quarter 2015 Financial Results
Omeros Corporation Reports Second Quarter 2015 Financial Results -- Conference Call Today at 4:30 p.m. ET -- PR Newswire
07.08.15 - PR Newswire
Omeros to Present at the 2015 Wedbush PacGrow Healthcare Conference
Omeros to Present at the 2015 Wedbush PacGrow Healthcare Conference PR Newswire
03.08.15 - PR Newswire
Omidria® Approved for Commercialization Throughout the European Union and Additional Countries
Omidria® Approved for Commercialization Throughout the European Union and Additional Countries -- Approval by the European Commission Follows Unanimous ...
31.07.15 - PR Newswire
Omeros Corporation to Announce Second Quarter 2015 Financial Results on August 10, 2015
Omeros Corporation to Announce Second Quarter 2015 Financial Results on August 10, 2015 PR Newswire
23.07.15 - PR Newswire
FDA Grants "Fast Track" to Omeros' Complement Inhibitor OMS721 for aHUS
FDA Grants "Fast Track" to Omeros' Complement Inhibitor OMS721 for aHUS -- Phase 2 Trial and Compassionate Use Program Advance -- PR Newswire
11.08.14 - PR Newswire
Omeros Corporation Reports Second Quarter 2014 Financial Results
Omeros Corporation Reports Second Quarter 2014 Financial Results -- FDA Approval of Omidria™ Received on May 30, 2014 - PR Newswire
08.08.14 - PR Newswire
Omeros to Present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference
Omeros to Present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference PR Newswire
02.06.14 - PR Newswire
Omeros Receives FDA Approval of Omidria™ for Use in Cataract and Other Intraocular Lens Replacement Procedures
Omeros Receives FDA Approval of Omidria™ for Use in Cataract and Other Intraocular Lens Replacement Procedures -- Omeros to Host Conference Call Today at 4:30 p.m. ET -- PR ...
12.05.14 - PR Newswire
Omeros Corporation Reports First Quarter 2014 Financial Results
Omeros Corporation Reports First Quarter 2014 Financial Results -- Secures Additional $50.4 Million in Cash in 1Q 2014 -- PR Newswire
07.04.14 - PR Newswire
Omeros to Present at the 13th Annual Needham Healthcare Conference
Omeros to Present at the 13th Annual Needham Healthcare Conference PR Newswire
03.04.14 - PR Newswire
Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies
Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies -- Phase 2 Clinical Trial Planned to Begin This Quarter -- PR Newswire
01.04.14 - PR Newswire
Omeros Invited to Present on OMS824 Phase 2 Clinical Program at the Schizophrenia International Research Conference
Omeros Invited to Present on OMS824 Phase 2 Clinical Program at the Schizophrenia International Research Conference -- Conference Focuses on New Drug Development and ...
21.03.14 - PR Newswire
Omeros to Present at BioCentury Future Leaders in the Biotech Industry Conference
Omeros to Present at BioCentury Future Leaders in the Biotech Industry Conference PR Newswire
19.03.14 - PR Newswire
Omeros Closes $40.25 Million Public Offering of Common Stock
Omeros Closes $40.25 Million Public Offering of Common Stock PR Newswire
14.03.14 - PR Newswire
Omeros Prices $35.0 Million Public Offering of Common Stock
Omeros Prices $35.0 Million Public Offering of Common Stock PR Newswire

Newssuche

Videos

newspaper
06.05.24 +2,22%
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »